Naldemedine

CHEMBL2105755 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

570.6 g/mol

LogP

3.2

Phase

4

Used to relieve constipation caused by opioid pain medications, this drug blocks opioid receptors specifically in the gut without affecting pain relief in the brain. It helps restore normal bowel function in people taking opioids for chronic pain.

आणविक भार

570.6000 g/mol

LogP

3.20

TPSA

141.00 Å²

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अग्नाशय कैंसर ओवेरियन कैंसर कोलोरेक्टल कैंसर थायरॉइड कैंसर नॉन-स्मॉल सेल लंग कैंसर प्रोस्टेट कैंसर मूत्राशय कैंसर स्तन कैंसर

क्रिया का तंत्र

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1

InChI

InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1

Molecular Formula

C32H34N4O6

HBD / HBA

4 / 9

घूर्णनीय बंधन

6

भारी परमाणु

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Used to relieve constipation caused by opioid pain medications, this drug blocks opioid receptors specifically in the gut without affecting pain relief in the brain. It helps restore normal bowel function in people taking opioids for chronic pain.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Naldemedine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105755. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 54732242. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Naldemedine PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C32H34N4O6
पर्यायवाची: 1

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.